---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-050335"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-04-23T23:59:59+00:00"
generated_at: "2026-06-03T12:06:45.999442+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M

## Summary
- ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.
- Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.
- Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.
- Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.
- About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months.

## SEC filing metadata
- accession: 0001104659-24-050335
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-04-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/0001104659-24-050335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/tm2412282d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-050335
- JSON: https://secwatch.observer/filing/0001104659-24-050335.json
- Plain text: https://secwatch.observer/filing/0001104659-24-050335.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported first quarter 2024 results: revenue Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023., net income Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter. Guidance raised.
  - Period: first quarter 2024
  - Revenue: Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023.
  - Net income: Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter
  - Guidance: raised
  - Result: reported results
  source text: On April 23, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/0001104659-24-050335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.